CN Patent

CN102088993A — 炎症的治疗方法

Assigned to Carolus Therapeutics Inc · Expires 2011-06-08 · 15y expired

What this patent protects

在某些实施例中，本文公开一种治疗MIF介导的病症的方法。在一些实施例中，所述方法包含投予一种活性剂，所述活性剂可抑制(i)MIF与CXCR2和CXCR4的结合，和/或(ii)MIF对CXCR2和CXCR4的活化；(iii)MIF形成同源多聚体的能力；或其组合。

USPTO Abstract

在某些实施例中，本文公开一种治疗MIF介导的病症的方法。在一些实施例中，所述方法包含投予一种活性剂，所述活性剂可抑制(i)MIF与CXCR2和CXCR4的结合，和/或(ii)MIF对CXCR2和CXCR4的活化；(iii)MIF形成同源多聚体的能力；或其组合。

Drugs covered by this patent

Xolremdi (MAVORIXAFOR) · X4 Pharms

Patent Metadata

Patent number: CN102088993A
Jurisdiction: CN
Classification: —
Expires: 2011-06-08
Drug substance claim: No
Drug product claim: No
Assignee: Carolus Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.